Analyst Ratings February 12, 2026

Canaccord Sticks With Buy on Neurocrine After Strong Q4; Crenessity Outperforms Expectations

Analyst retains $164 price target as Neurocrine posts solid quarter and outlines 2026 Ingrezza outlook

By Marcus Reed NBIX
Canaccord Sticks With Buy on Neurocrine After Strong Q4; Crenessity Outperforms Expectations
NBIX

Canaccord Genuity maintained its Buy rating and $164.00 price target on Neurocrine Biosciences (NASDAQ:NBIX) following the company's fourth-quarter 2025 results. The firm highlighted robust performance from both Ingrezza and the recently launched Crenessity, while flagging higher-than-expected expenses and a lack of near-term pipeline catalysts as potential headwinds.

Key Points

  • Canaccord Genuity reaffirmed a Buy rating and a $164.00 price target on Neurocrine following Q4 2025 results; InvestingPro's Fair Value suggests Neurocrine may be undervalued at a $13.7 billion market cap.
  • Ingrezza generated $658 million in Q4 sales, slightly below the $662 million FactSet consensus; Crenessity outperformed with $135 million in quarterly sales versus Canaccord's $99 million estimate and consensus of $117 million.
  • Neurocrine set 2026 Ingrezza guidance of $2.7-2.8 billion and reported 19.6% revenue growth over the past twelve months; analysts remain broadly positive with price targets from $140 to $217.

Canaccord Genuity reaffirmed a Buy recommendation and left its $164.00 price target intact for Neurocrine Biosciences (NASDAQ:NBIX) after the company released fourth-quarter 2025 results on Tuesday. That price objective sits close to InvestingPro's Fair Value estimate, which indicates the company, with a market capitalization of $13.7 billion, may be trading below intrinsic value.

For the quarter, Neurocrine reported Ingrezza sales of $658 million, a figure marginally under the FactSet consensus of $662 million. Ingrezza is approved to treat tardive dyskinesia and Huntington's chorea and remains a core revenue driver for the business.

The recently launched Crenessity - Neurocrine's therapy for classic congenital adrenal hyperplasia - delivered quarterly sales of $135 million, materially above expectations. Canaccord had forecast $99 million for the product, while consensus stood at $117 million.

Looking ahead, Neurocrine provided an outlook for Ingrezza sales in 2026 of $2.7-2.8 billion, a range Canaccord describes as "achievable/beatable." The company did not provide formal guidance for Crenessity, but management signaled an expectation of continued growth for the newly introduced therapy. The outlook follows a reported 19.6% revenue increase over the last twelve months.

Canaccord also drew attention to cost pressures. The firm noted that Neurocrine's expense guidance came in higher than some investors were anticipating, and it emphasized that significant pipeline catalysts are not expected until 2027 or later. Those factors, Canaccord warned, could weigh on the stock in the near term despite the firm's longer-term bullish view.

Even with those caveats, Canaccord maintained that Neurocrine is "undervalued on approved products" and presents an opportunity ahead of when the company's "relatively large pipeline" begins to be reflected in valuation. The shares currently trade at a price-to-earnings ratio of 33.3, a level InvestingPro characterizes as a high earnings multiple given near-term growth expectations. Across the analyst community, sentiment skews positive, with a strong buy consensus and price targets spanning $140 to $217.

Additional detail from Neurocrine's quarter shows the company beat expectations on both earnings per share and revenue. Reported EPS was $1.88 versus a forecast of $1.86, while total revenue reached $805.5 million, narrowly above the $802.45 million estimate. These metrics underscore the company's solid finish to the year.

In separate analyst activity, H.C. Wainwright reduced its price target on Neurocrine to $192 from $198 but kept a Buy rating in place. The change follows a year where Ingrezza saw record prescription levels and Crenessity completed a successful launch year, developments that point to ongoing commercial momentum.


Implications for markets and sectors

  • Biotechnology and pharmaceutical equities may be influenced by Neurocrine's commercial execution and the timeline for late-stage pipeline catalysts.
  • Health-care investors tracking drug launches and prescription trends will likely monitor Crenessity's trajectory closely, given its strong initial sales.

Risks

  • Higher-than-expected expense outlook could pressure near-term profitability and share performance - this primarily affects healthcare and biotech investor sentiment.
  • Meaningful pipeline catalysts are not anticipated until 2027 or later, which may limit near-term upside tied to new approvals or data readouts - this impacts valuations across the biotech sector.
  • The stock trades at a P/E of 33.3, a relatively high multiple versus near-term growth, which could increase sensitivity to execution risks and market rotation away from growth stocks.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026